These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 35526614)

  • 1. Unmet needs in glaucoma therapy: The potential role of hydrogen sulfide and its delivery strategies.
    Mhatre S; Opere CA; Singh S
    J Control Release; 2022 Jul; 347():256-269. PubMed ID: 35526614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of Aqueous Humor Dynamics by Hydrogen Sulfide: Potential Role in Glaucoma Pharmacotherapy.
    Ohia SE; Robinson J; Mitchell L; Ngele KK; Heruye S; Opere CA; Njie-Mbye YF
    J Ocul Pharmacol Ther; 2018; 34(1-2):61-69. PubMed ID: 29215951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relevant variations and neuroprotecive effect of hydrogen sulfide in a rat glaucoma model.
    Huang S; Huang P; Liu X; Lin Z; Wang J; Xu S; Guo L; Leung CK; Zhong Y
    Neuroscience; 2017 Jan; 341():27-41. PubMed ID: 27890826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydrogen Sulfide Protects Retinal Ganglion Cells Against Glaucomatous Injury In Vitro and In Vivo.
    Liu H; Anders F; Thanos S; Mann C; Liu A; Grus FH; Pfeiffer N; Prokosch-Willing V
    Invest Ophthalmol Vis Sci; 2017 Oct; 58(12):5129-5141. PubMed ID: 28986598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hydrogen sulfide supplement preserves mitochondrial function of retinal ganglion cell in a rat glaucoma model.
    Huang S; Huang P; Yu H; Chen J; Liu X; Wang J; Shen X; Zhong Y
    Cell Tissue Res; 2022 Aug; 389(2):171-185. PubMed ID: 35593936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained-Release Delivery System of a Slow Hydrogen Sulfide Donor, GYY 4137, for Potential Application in Glaucoma.
    Patil A; Singh S; Opere C; Dash A
    AAPS PharmSciTech; 2017 Aug; 18(6):2291-2302. PubMed ID: 28101725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Upregulation of the endothelin A (ET
    McGrady NR; Minton AZ; Stankowska DL; He S; Jefferies HB; Krishnamoorthy RR
    BMC Neurosci; 2017 Mar; 18(1):27. PubMed ID: 28249604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Purinergic dysregulation causes hypertensive glaucoma-like optic neuropathy.
    Shinozaki Y; Kashiwagi K; Namekata K; Takeda A; Ohno N; Robaye B; Harada T; Iwata T; Koizumi S
    JCI Insight; 2017 Oct; 2(19):. PubMed ID: 28978804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topical administration of rapamycin promotes retinal ganglion cell survival and reduces intraocular pressure in a rat glaucoma model.
    Wang F; Ma F; Song Y; Li N; Li X; Pang Y; Hu P; Shao A; Deng C; Zhang X
    Eur J Pharmacol; 2020 Oct; 884():173369. PubMed ID: 32712092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated IOP alters the space-time profiles in the center and surround of both ON and OFF RGCs in mouse.
    Sabharwal J; Seilheimer RL; Tao X; Cowan CS; Frankfort BJ; Wu SM
    Proc Natl Acad Sci U S A; 2017 Aug; 114(33):8859-8864. PubMed ID: 28760976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroprotection in the treatment of glaucoma--A focus on connexin43 gap junction channel blockers.
    Chen YS; Green CR; Danesh-Meyer HV; Rupenthal ID
    Eur J Pharm Biopharm; 2015 Sep; 95(Pt B):182-93. PubMed ID: 25676338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanoencapsulated hybrid compound SA-2 with long-lasting intraocular pressure-lowering activity in rodent eyes.
    Stankowska DL; Millar JC; Kodati B; Behera S; Chaphalkar RM; Nguyen T; Nguyen KT; Krishnamoorthy RR; Ellis DZ; Acharya S
    Mol Vis; 2021; 27():37-49. PubMed ID: 33633438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic Drugs and Devices for Tackling Ocular Hypertension and Glaucoma, and Need for Neuroprotection and Cytoprotective Therapies.
    Sharif NA
    Front Pharmacol; 2021; 12():729249. PubMed ID: 34603044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of potential novel glaucoma therapeutic options independent of intraocular pressure.
    Shalaby WS; Ahmed OM; Waisbourd M; Katz LJ
    Surv Ophthalmol; 2022; 67(4):1062-1080. PubMed ID: 34890600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intraocular pressure and glaucoma.
    Ofri R
    Vet Clin North Am Exot Anim Pract; 2002 May; 5(2):391-406, vii-viii. PubMed ID: 12170640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydrogen sulfide supplement attenuates the apoptosis of retinal ganglion cells in experimental glaucoma.
    Huang S; Huang P; Lin Z; Liu X; Xu X; Guo L; Shen X; Li C; Zhong Y
    Exp Eye Res; 2018 Mar; 168():33-48. PubMed ID: 29326065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adenosine, adenosine receptors and glaucoma: an updated overview.
    Zhong Y; Yang Z; Huang WC; Luo X
    Biochim Biophys Acta; 2013 Apr; 1830(4):2882-90. PubMed ID: 23328492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted delivery of LM22A-4 by cubosomes protects retinal ganglion cells in an experimental glaucoma model.
    Ding Y; Chow SH; Chen J; Brun APL; Wu CM; Duff AP; Wang Y; Song J; Wang JH; Wong VHY; Zhao D; Nishimura T; Lee TH; Conn CE; Hsu HY; Bui BV; Liu GS; Shen HH
    Acta Biomater; 2021 May; 126():433-444. PubMed ID: 33774200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacotherapies for glaucoma.
    Toris CB
    Curr Mol Med; 2010 Dec; 10(9):824-40. PubMed ID: 21091423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hydrogen Sulfide and
    Liu H; Mercieca K; Anders F; Prokosch V
    J Ophthalmol; 2020; 2020():8642135. PubMed ID: 32351728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.